A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 12 Nov 2018 Planned End Date changed from 17 Jul 2024 to 16 Jul 2024.
- 14 Aug 2018 Planned End Date changed from 12 Jun 2024 to 17 Jul 2024.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.